BioSyent Inc. (CVE:RX) Insider Sells C$500,500.00 in Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 65,000 shares of the firm’s stock in a transaction dated Thursday, April 13th. The shares were sold at an average price of C$7.70, for a total transaction of C$500,500.00.

FAX Capital Corp. also recently made the following trade(s):

• On Friday, November 22nd, FAX Capital Corp. sold 230,800 shares of BioSyent stock. The shares were sold at an average price of C$11.12, for a total transaction of C$2,566,496.00.

BioSyent Price Performance

Shares of CVE:RX traded down C$0.18 during trading hours on Tuesday, hitting C$11.52. 395 shares of the company’s stock traded hands, compared to its average volume of 6,849. BioSyent Inc. has a 52 week low of C$8.24 and a 52 week high of C$11.74. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13. The company’s fifty day simple moving average is C$11.06 and its two-hundred day simple moving average is C$10.29. The company has a market cap of C$133.52 million, a price-to-earnings ratio of 19.50 and a beta of 0.93.

BioSyent (CVE:RX) last announced its earnings results on Monday, August 26th. The company reported C$0.13 EPS for the quarter, hitting the consensus estimate of C$0.13. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. The company had revenue of C$8.95 million during the quarter, compared to analysts’ expectations of C$8.80 million. As a group, equities analysts anticipate that BioSyent Inc. will post 0.6944444 EPS for the current fiscal year.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.